Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMYMP) EBITDA Margin (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed EBITDA Margin for 17 consecutive years, with 8.6% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 615.0% to 8.6% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 14.05% through Dec 2025, up 3193.0% year-over-year, with the annual reading at 14.04% for FY2025, 3193.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 8.6% at Bristol Myers Squibb, down from 18.34% in the prior quarter.
  • The five-year high for EBITDA Margin was 21.09% in Q4 2021, with the low at 99.16% in Q1 2024.
  • Average EBITDA Margin over 5 years is 8.64%, with a median of 13.91% recorded in 2022.
  • The sharpest move saw EBITDA Margin soared 14181bps in 2021, then tumbled -11834bps in 2024.
  • Over 5 years, EBITDA Margin stood at 21.09% in 2021, then tumbled by -34bps to 13.87% in 2022, then decreased by -6bps to 13.09% in 2023, then plummeted by -81bps to 2.45% in 2024, then skyrocketed by 251bps to 8.6% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 8.6%, 18.34%, and 9.63% for Q4 2025, Q3 2025, and Q2 2025 respectively.